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Purpose: Associations between population-based screening, breast carcinoma detection modes and breast carcinoma
death have not been studied using nationwide data at individual level. We evaluated these in Finland, where invitational
age is gradually expanding from 50–59 to 50–69 years in 2008–2017. We also predicted breast carcinoma patterns in
2020 to assess the impact of changing invitational policy on breast carcinoma incidence and mortality.
Methods: The data included breast carcinomas in 2000–2010 (n = 48 040), and deaths due to these carcinomas
(n = 4722). We divided carcinomas into those detected before or after the screening age, and those detected at the
screening age. The latter was further divided into screen-detected and interval carcinomas, and carcinomas in the
non-attendees. The prediction of future patterns was based on incidence data from the ten-year period 1998–2007
preceding the period of expanding invitational age in the national programme.
Results: Approximately 13% of in situ carcinomas were detected before, 29% after, and 57% at the screening age. In
invasive cancers, the percentages were 16%, 42%, and 42%, respectively. At the screening age, more than half of invasive
cancers were screening-detected, one quarter interval cancers, and one out of six cancers in the non-attendees. Almost
60% of breast cancer deaths were due to cancers detected after the screening age. By 2020, breast cancers detected at
the screening age will increase from 42% to 65%, and breast cancers detected by screening from 23% to 38%.
Conclusions: The study demonstrates a novel approach to examine associations between breast carcinoma incidence
and mortality within and outside population-based screening. The results show mammography screening having a
distinct role in overall breast carcinoma incidence and mortality.
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Population-based mammography screening is a multistep
process starting with identification and invitation of the
target population, and continuing further to mammog-
raphy test, and prospective recall examinations, cancer
management and care (Vainio and Bianchini 2002; Perry
et al. 2008). In the screening target population, breast
cancers are detected among attendees within the screen-
ing programme, or outside the programme either among
non-attendees or among attendees without findings in
their previous screening episode. Additionally, a consider-
able amount of breast carcinomas are detected in women* Correspondence: tytti.sarkeala@cancer.fi
1Mass Screening Registry/Finnish Cancer Registry, Unioninkatu 22, Helsinki
00130, Finland
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in any medium, provided the original work is pwho not yet have reached, or already have passed, the
screening age.
Monitoring of the European population-based mammog-
raphy screening has shown significant variation between
programmes and centres in invitational coverage, attend-
ance, and sensitivity and specificity of screening (Sarkeala
et al. 2004; Giordano et al. 2012; Hofvind et al. 2012).
Relationships between the screening process (recall rate),
the screening performance (sensitivity), and the mortality
reduction due to screening have also been shown to be
non-straightforward (Sarkeala et al. 2006). The above
imply delicate balance between benefits and harms in the
European population-based mammography screening.
Variation in the screening performance (Sarkeala et al.
2006; Törnberg et al. 2010) – as well as in the coveragean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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detected within and outside the organised screening.
Furthermore, a considerable percentage of breast carcin-
omas detected outside screening may be asymptomatic
with a prognostic profile comparable to that of the screen-
detected carcinomas (Sarkeala et al. 2004; 2006; Hoff et al.
2012). Hence it is important to assess the detection of
breast carcinomas in the whole female population.
Albeit recommended by the European Network of Can-
cer Registries (European Network for Cancer Registries
2014), only few European countries have so far assessed
the impact of population-based mammography screening
on the distribution of all breast carcinomas. This would,
however, help to assess associations between breast car-
cinoma diagnostics and treatment, and to clarify impacts
of population-based mammography screening on breast
carcinoma incidence and mortality.
The aim of the current study is to examine detection
modes of incident breast carcinomas and breast carcin-
oma deaths in relation to invitation and participation to
population-based mammography screening. The study uses
all breast carcinomas among Finnish women in 2000–2010,
and deaths due to these carcinomas. Additionally, the study
analyses distribution and trend of breast carcinomas in
areas practicing various invitational policies, and predicts
breast cancer patterns in 2020, when the national mam-
mography programme in Finland will cover all women
aged 50–69 years.
Material and methods
In Finland, population-based mammography screening was
started gradually in 1986–1987. The screening programme
was fully implemented in the beginning of 1992 for all
women aged 50–59 years. Detailed description of the
programme has been given earlier (Sarkeala et al. 2004;
2006). Based on the Government Degree on Screenings
from 2007, the invitational age of the screening programme
is gradually expanding from 50–59 years to 50–69 years
(Government Decree on Screenings (1339/2006)). Women
born in 1947 are the first to receive a regular, biennial
invitation until the age of 69 years. In the study period
2000–2010, the Finnish municipalities thus have invited
all women aged 50–59 years regularly, and women aged
60–69 years by an annually expanding protocol to
population-based mammography screening. The city of
Turku, however, has carried out an exceptional invita-
tional protocol throughout 2000–2010 by inviting women
aged 50–69 years regularly and women aged 40–49 and
70–74 years irregularly to mammography screening.
Since the start of the national programme, the data on
mammography screening have been registered centrally
to the Mass Screening Registry. The coverage of regis-
tration has increased steadily from 70% to more than
98% from the early 1990’s (Mass Screening Statistics inFinland 2014). The clinical and pathological data on all
breast carcinomas in Finland have been recorded by the
Finnish Cancer Registry since 1953.
We assessed the detection of all breast carcinomas di-
agnosed in Finland in the period 2000–2010 (n = 48 040)
by linking information on breast carcinomas and on
screening invitations and findings at an individual level.
To assess relationships between breast cancer detection
and breast cancer death, we also linked the incident breast
carcinoma cases with deaths from breast cancer in
2000–2010. The linkage was done using a unique personal
identifier (social security number) as a key. Within this
linkage procedure, we divided breast carcinomas into
three categories: carcinomas detected before or after the
screening age (before the first and after the last invitation
to screening) and carcinomas detected at the screening
age. The categorization was based on novel recommen-
dations on the categories of detection, developed in an
expert work group in a cancer-registry-driven Eurocourse
project (EUROCOURSE: EUROpe against Cancer 2014).
A similar assessment has earlier been reported for cervical
carcinomas in Finland (Lönnberg et al. 2013).
Carcinomas detected at the screening age were further
divided into screen-detected carcinomas, interval carcin-
omas, carcinomas among the non-attendees, and carcin-
omas among women, whose data on screening invitations
and results had not been sent to the Mass Screening
Registry (non-registered carcinomas). Screen-detected
carcinomas were carcinomas diagnosed among the screen-
ing attendees within six months after the previous
population-based mammography test with a positive
result both from the test and the recall examinations.
Interval carcinomas were carcinomas diagnosed among
the screening attendees in between two subsequent
invitations with a) a negative result from the previous
test, b) a positive result from the previous test and a
negative result from the previous recall examinations,
or c) a positive result from the previous test and the
recall examinations with a date of diagnosis six months
after the date of mammography (women having both
screen-detected and interval breast cancers).
We report the incident breast carcinoma categories
by behaviour (in situ carcinoma of the breast; invasive
carcinoma i.e. breast cancer), morphology (ductal, lobular,
others), and stage (local, metastasized, unknown). The
ductal carcinomas are those with ICD-O-3-codes M8500-
07, and lobular carcinomas those with an ICD-O3-code
M8520. The metastasized breast cancers are those metas-
tasized to regional lymph nodes only (regional metastasis)
or further and/or to adjacent tissues (distant metastasis).
To examine the proportions of screen-detected and
interval breast cancers and breast cancers among the
non-attendees out of all breast cancers in the screening
target population in 2000–2010, we applied Poisson
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2003–2006, and 2007–2010) estimates of incidence rate
ratio (IRR) were adjusted for categorical age (50–54,
55–59, 60–64, and 65–69 years).
Based on the varying invitational policies between
the rest of Finland and the Turku area in 2000–2010,
and incidence prediction by an additive Poisson model
(Dyba and Hakulinen 1994), we estimated the distribution
of invasive breast cancers in Finland in 2020, when all
women aged 50–69 years are expected to get an invita-
tion to mammography screening in every two years
(Government Decree on Screenings (1339/2006)). The
Poisson model allowed for different age-specific changes
of incidence rates on an additive scale over time (Dyba
and Hakulinen 2000). The prediction was based on breast
cancer incidence in ages 30–89 years in the ten-year
period 1998–2007 preceding the expansion period of the
invitational age in the national screening programme. The
predicted, age-specific numbers of breast cancers in ages
30–89 years in 2020 were divided into breast carcinoma
categories using information on breast cancer detection
from 2000–2010 from Turku area for ages 60–79 years,
and corresponding information from the rest of Finland
for ages less than 60 and more than 79 years.
Results
A total of 3468 in situ carcinomas and 44 572 invasive
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Figure 1 Breast carcinoma detection modes in 2000-2010. (a) In situ bre
screening in the whole country. (b) In situ breast carcinomas and invasive bre(Figure 1a). Approximately 13% of in situ carcinomas were
detected before the first, 29% after the last invitation to
screening, and 57% at the screening age. In invasive
cancers, the corresponding percentages were 16%, 42%,
and 42%. At the screening age, more 55% of the invasive
breast cancers were detected by screening, 28% as interval
cancers, and 14% among the non-attendees. In Turku
area, where women aged 50–69 had been invited regularly
to mammography screening throughout 2000–2010,
most invasive breast cancers (64%) were detected at the
screening age (Figure 1b).
At the screening age, most breast carcinomas were
detected in ages 50–69 years (Table 1). Few cases in age
groups less than 50 and over 69 years were detected in
Turku city, where the age groups 40–49 and 70–74 years
had been invited to population-based screening irregu-
larly in 2000–2007. Most interval cancers were due to
negative result from the mammography test.
Localized (63%) and regionally metastasized (29%) were
the most common stages of screen-detected cancers
(Table 2). In breast cancers among the non-attendees,
the corresponding proportions were 43% and 36%, and
in the interval breast cancers 49% and 38%, respectively,
showing that stages with a favourable prognosis were
largely diagnosed in the screening target population also
outside the screening programme. The stage distribution
of breast cancers detected before the screening age resem-
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Invasive
ast carcinomas and invasive breast cancers in relation to invitation to
ast cancers in relation to invitation to screening in the Turku area.
Table 1 Breast carcinomas by behaviour and age in relation to invitation to screening in the screening target
population in 2000–2010
In situ
< 50 yrs 50-69 yrs >69 yrs Total
N (%) N (%) N (%) N (%)
ALL 19 (100) 1948 (100) 18 (100) 1 985 (100)
Non-attendee 2 (11) 165 (9) 2 (11) 169 (9)
Screen-detected 9 (47) 1411 (72) 7 (39) 1 427 (72)
Interval 2 (11) 346 (18) 8 (44) 356 (18)
test- 2 (11) 252 (13) 6 (33) 260 (13)
test+, recall- - (−) 61 (3) 2 (11) 63 (3)
test+, recall+, dg>6 mths - (−) 33 (2) - (−) 33 (2)
Non-registered 6 (32) 26 (1) 1 (6) 33 (2)
Invasive
< 50 yrs 50-69 yrs >69 yrs Total
N (%) N (%) N (%) N (%)
ALL 227 (100) 18 139 (100) 198 (100) 18 564 (100)
Non-attendee 31 (14) 2 512 (14) 31 (16) 2 574 (14)
Screen-detected 70 (31) 10 242 (56) 70 (35) 10 382 (56)
Interval 46 (21) 5 093 (28) 95 (48) 5 234 (28)
test- 42 (19) 4 529 (25) 80 (40) 4 651 (25)
test+, recall- 4 (2) 479 (3) 9 (5) 492 (3)
test+, recall+, dg>6 mths - (−) 85 (<1) 6 (3) 91 (<1)
Non-registered 80 (35) 292 (2) 2 (1) 374 (2)
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cers detected after the screening age to that of the interval
breast cancers (Table 2). The morphological distribution
of invasive breast cancers was similar within and outside
the programme.
The absolute numbers of in situ carcinomas and inva-
sive breast cancers increased clearly from 2000 to 2010Table 2 Invasive breast cancers by stage and morphology in
Before screening age At screening age
Non-attendees Screen-detected
N (%) N (%) N (%)
ALL 7 129 (100) 2 574 (100) 10 382 (100)
Local 3056 (42) 1 110 (43) 6 495 (63)
Metastasis 3698 (51) 1 272 (50) 3 290 (31)
regional 3 140 (44) 938 (36) 3024 (29)
distant 427 (6) 284 (11) 144 (1)
not specified 131 (1) 50 (3) 122 (1)
Unknown 375 (7) 192 (7) 597 (6)
Ductal 5 586 (78) 1 866 (72) 7 976 (77)
Lobular 1 010 (14) 426 (17) 1 672 (16)
Others 533 (8) 282 (11) 734 (7)(Figure 2a). At the screening age, the proportion of
interval breast cancers was 13% lower in the expansion
period 2007–2010 compared to the period 2000–2002
(IRR 0.87, 95% confidence interval (CI) 0.81-0.93%)
(Figure 2b, Table 3). This was, however, mainly attribut-
able to the ages 60–69 years (Table 3). The increase in
the proportion of breast cancers among the non-attendeesrelation to invitation to screening in 2000–2010
After screening age Total
Interval Non-registered
N (%) N (%) N (%) N (%)
5 234 (100) 374 (100) 18 879 (100) 44 752 (100)
2 563 (49) 195 (52) 9 089 (48) 22 508 (50)
2 392 (46) 157 (42) 7 881 (42) 18 690
2 015 (38) 138 (37) 5 695 (30) 14 950 (42)
280 (5) 17 (5) 1 740 (9) 2 892 (6)
97 (3) 2 (<1) 446 (2) 848 (2)
279 (5) 22 (6) 1 909 (10) 3 374 (8)
3 767 (72) 287 (77) 13 164 (70) 32 646 (73)
1 037 (20) 66 (18) 3 395 (18) 7 606 (17)
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Figure 2 Breast carcinoma detection modes over 2000-2010. (a) Absolute numbers of in situ breast carcinomas and invasive breast cancers
in relation to invitation to screening, all ages. (b) Proportion of in situ breast carcinomas and invasive breast cancers in relation to invitation to
screening; all ages, ages 50-59, and ages 60-69 years.
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Table 3 Development of breast cancers among the non-
attendees, screen-detected breast cancers, and interval
breast cancers from 2000–2002 to 2007–2010 (expansion
period) by incidence rate ratios (IRR) with 95% confidence
intervals (95% CI) in ages 50–59, 60–69, and 50–69 years
50-59 years
Non-attendee Screen-detected Interval
IRR 95% CI IRR 95% CI IRR 95% CI
Period
2000-2002 1 1 1
2003-2006 0.98 0.87-1.10 1.07 1.01-1.13 0.97 0.90-1.05
2007-2010 1.23 1.09-1.38 1.05 0.99-1.11 0.92 0.85-0.99
60-69 years
Non-attendee Screen-detected Interval
IRR 95% CI IRR 95% CI IRR 95% CI
Period
2000-2002 1 1 1
2003-2006 0.83 0.65-1.06 1.07 0.95-1.21 1.09 0.93-1.29
2007-2010 1.04 0.84-1.29 1.26 1.13-1.41 0.77 0.66-0.89
50-69 years
Non-attendee Screen-detected Interval
IRR 95% CI IRR 95% CI IRR 95% CI
Period
2000-2002 1 1 1
2003-2006 0.95 0.85-1.06 1.06 1.01-1.12 0.99 0.93-1.07
2007-2010 1.18 1.07-1.31 1.11 1.05-1.16 0.87 0.81-0.93
Table 4 Invasive breast cancers by behaviour in relation to
invitation to screening in the Finnish female population in
the study period 2000–2010 and the corresponding
predicted values with 95% confidence intervals (CI) in 2020
2000-2010 2020
N (%) N 95% CI (%)
ALL 44 572 (100) 5 454 (100)
Before screening age 7 129 (16) 541 (496–589) (10)
At screening age 18 564 (42) 3 545 (3 429–3 662) (65)
non-attendee 2 948 (7) 410 (371–451) (8)
screen-detected 10 291 (23) 2 076 (1 988–2 166) (38)
interval 5 325 (12) 1 059 (996–1 124) (19)
After screening age 18 879 (42) 1 368 (1 296–1 441) (25)
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18% (IRR 1.18, 95% CI 1.07-1.31) than that of the screen-
detected breast cancers, 11% (IRR 1.11, 95% CI 1.05-1.16)
(Table 3). The increase in non-attendees was due to ages
50–59 years (Table 3), which were covered by the screen-
ing programme already before the year 2000.
Compared to the study period 2000–2010, the propor-
tion of breast cancers detected at the screening age in
2020 is, according to the prediction, going to increase
from 42% to 65% (Table 4). Of these, the proportion of
screen-detected and interval cancers will increase, and the
proportion of breast cancers among the non-attendees
will remain more or less at the same level.
When assessing breast cancer deaths in 2000–2010,
those resulting from breast cancers detected throughout
2000–2010 (potential follow-up time 1–11 years, n = 4722)
were mostly, 59%, due to breast cancers detected after the
screening age (Figure 3). The same phenomenon was also
seen in breast cancers detected during the year 2000 only
(potential follow-up time 11 years, n = 724). Only 7% of
breast cancer deaths were due to breast cancers detected
by screening. In interval cancers and cancer among the
non-attendants, the corresponding proportions were 9%
and 7%.Discussion
We examined all breast carcinomas in Finland in relation
to invitation, attendance and findings in the population-
based mammography screening, and deaths due to these
carcinomas. We also assessed the impact of the expansion
of invitational age on the detection of breast carcinomas
in the future. To our knowledge, the study is the first to
evaluate associations between population-based screening,
breast carcinoma detection and breast carcinoma death in
a nationwide female population.
According to our prediction, more than 60% of invasive
breast cancers will be diagnosed at the screening target
age and approximately 40%, respectively, directly by
screening when the whole female target population
aged 50 to 69 years will be invited to screening in
Finland in 2020. Since breast cancers detected after the
last screening round will also be affected by the preced-
ing period of population-based screening (Day et al.
1989), screening will be involved in the characteristics
of most incident breast carcinomas in 2020. Moreover,
most deaths due to breast carcinoma in the study
period were due to breast cancers detected after the
screening age suggesting that the expanding mammog-
raphy programme will also have a considerable impact
on the future breast cancer mortality.
In the current data, as much as 40% of in situ breast
carcinomas were detected before or after the screening
age. Additionally, 10% of them were interval cancers,
and 5% were detected in the non-attendees of screening.
All these refer to high opportunistic activity and should be
studied further. Unfortunately, the opportunistic mammog-
raphy screening is not registered in Finland, and the
level of this phenomenon, therefore, is difficult to meas-
ure. Other European countries have also reported increase
in opportunistic activity due to population-based screen-
ing (Boncz et al. 2008).
The proportion of interval cancers in the whole screen-
ing target population was 28%, and among the screening
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Figure 3 Death from breast cancer in relation to breast carcinoma detection modes. (a) Both diagnosis and death in 2000-2010. (b) Diagnosis
in 2000, death in 2000-2010.
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screening attendees measured by the detection method
was 35%, and there was an increasing trend in the interval
cancer proportion (Sarkeala et al. 2006). According to the
current results, the reported increase in the early 2000’s
seems to have turned to a decrease after the year 2007
when the expansion of invitational age in the Finnish
mammography programme started. In women aged 60–
69 years, the interval cancer occurrence has consistently
been reported to be smaller than in the younger target
population (Sarkeala et al. 2006; Törnberg et al. 2010).
Nonetheless, also trends in the access to mammograms
and/or other diagnostic activities outside screening may
have affected the phenomenon.The increase in the proportion of breast cancers among
the non-participants – which was evident in ages 50–59
years – raises concern on the development of attendance
rate in the Finnish mammography programme. According
to the national statistics, overall attendance to screening
has decreased during the 2000s from approximately 87 to
85 percent (Government Decree on Screenings (1339/
2006)). Compared to other European countries, the over-
all rate in Finland is, however, still among the highest
(Giordano et al. 2012).
Approximately 40% of breast carcinoma cases and
more than half of breast cancer deaths were due to
breast cancers diagnosed after the screening age. This
was similarly evident in breast cancers detected in the
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between 1 to 11 years) and in breast cancers detected
solely during the year 2000 (potential follow-up time
11 years). In both settings, there were very few deaths due
to in situ carcinoma. Also the proportion of deaths due to
screen-detected cancers was small compared to the pro-
portion they represented in the distribution of cancers
(7% vs. 23%) whereas the proportion of deaths due to
breast cancers among non-attendants (7% vs. 6%) and due
to interval breast cancers (9% vs. 12%) was more or less
similar to that of cancer distribution.
According to the prediction, the proportion of breast
cancers detected at the screening age will increase from
around 40% to more than 60% in Finland in 2020. When
assessing this information in line with the information on
breast cancer deaths, two issues arise. First, effectiveness
of breast cancer screening will probably improve since
older women will be involved in the programme - and
screening has been shown to be more effective among
women aged 60–69 years than at younger ages (Anttila
et al. 2008; Sarkeala et al. 2008a; Sarkeala et al. 2008b;
Otto et al. 2012; Njor et al. 2012). Second, expansion of
invitational age to 70–74 years should be taken into
consideration in future scenarios of the national prog-
ramme. Women aged 70–74 years have been invited to
population-based screening in the Netherlands since the
early 1998, and the results on performance and mortality
reduction have been encouraging (Broeders et al. 2002;
Fracheboud et al. 2006). In Finland, women aged 70–74
years have previously been invited to population-based
screening in the Turku city, where the most prominent
reduction in breast cancer mortality was observed in the
oldest age groups (Parvinen et al. 2006).
Current data will be utilized further to investigate
associations between breast carcinoma diagnostics, thera-
peutic activities, and breast carcinoma death within and
outside the screening target population (Lehtimäki et al.
2011; Haukka et al. 2011). Documentation outside the
target population may e.g. provide information on rea-
sons behind the reduction in breast cancer mortality in
women aged 40–49 years (Anttila and Martin-Moreno
2013), which recently has been reported from several
European countries. In the screening target population,
the data can be applied to examine over-diagnosis and
other disadvantages of screening (Hofvind et al. 2012;
Puliti et al. 2012; Welch and Black 2010; Esserman et al.
2013; Bleyer and Welch 2012). A 1-10% over-diagnosis in
a woman’s lifetime has been reported due to screening in
ages 50–69 years (Puliti et al. 2012). If the excess of 10%
in breast cancer incidence was attributed only to screen-
ing, approximately 25% (10/38*100) of screen-detected
breast cancers would represent over-diagnosis in the
current data (in 2020). However, stages with a favourable
prognosis were largely diagnosed also outside the organisedscreening in the current data. This refers that over-
diagnosis may be attributed also to interval breast cancers
and breast cancers detected from the non-attendees.
To conclude, screen-detected in situ and invasive car-
cinomas represented the largest category of breast carcin-
omas detected at the screening age. However, stages with
favourable prognosis were largely diagnosed also outside
the screening programme referring that over-diagnosis
may not solely be attributed to the programme. Most
breast cancer deaths were due to invasive breast cancers
detected after the screening age. Due to expanding invita-
tional age, the proportion of breast cancers detected at the
screening age and by screening will substantially increase
by 2020. These imply that organised screening will have a
distinct impact on overall breast cancer incidence and
mortality in the future.
Our study demonstrates a novel approach for cancer
registries to examine associations between breast cancer
detection and deaths due to breast cancer. The approach
requires, however, comprehensive data on screening and
cancer deaths from nationwide, high quality registers with
a 100% coverage and may therefore be unattainable for
some European countries. In countries with appropriate
databases, monitoring and evaluation of the impact of
population-based screening on the overall cancer burden
can be carried out on a regular basis.
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